North Brunswick, United States
LinusBio, founded in 2020, is a pioneering company operating at the forefront of Precision Exposome Medicine. Revolving around breakthrough science, the company focuses on patient-centric solutions within the biotechnology, health care, and pharmaceutical industries. Its innovative program pipeline is actively advancing the discovery of precision exposome medicine biomarkers and targets many diseases, including CNS disorders like autism spectrum disorder and amyotrophic lateral sclerosis, as well as illnesses in gastroenterology, renal disease, and oncology.
Headquartered in the United States, LinusBio represents a new frontier in medical practice by addressing historically challenging domains with no available molecular endpoints. Recently, the company secured a $6.15M in a Late VC investment dated 01 August 2024, signifying strong confidence from the investment community in its disruptive potential.
